Onofrj M - Search Results

1

Cerebral venous thrombosis without thrombocytopenia after a single dose of COVID-19 (Ad26.COV2.S) vaccine injection: a case report.

Di Pietro M, Dono F, Consoli S, Evangelista G, Pozzilli V, Calisi D, Barbone F, Bonanni L, Onofrj M, De Angelis MV, Sensi SL. Di Pietro M, et al. Among authors: onofrj m. Neurol Sci. 2022 May;43(5):2951-2956. doi: 10.1007/s10072-022-05965-5. Epub 2022 Feb 25. Neurol Sci. 2022. PMID: 35217969 Free PMC article.

2

Leucopenia induced by low dose clozapine in Parkinson's disease recedes shortly after drug withdrawal. Clinical case descriptions with commentary on switch-over to olanzapine.

Onofrj M, Thomas A, Bonanni L, Iacono D, Gambi F. Onofrj M, et al. Neurol Sci. 2000 Aug;21(4):209-15. doi: 10.1007/s100720070078. Neurol Sci. 2000. PMID: 11214659

3

Donepezil, rivastigmine, and vitamin E in Alzheimer disease: a combined P300 event-related potentials/neuropsychologic evaluation over 6 months.

Thomas A, Iacono D, Bonanni L, D'Andreamatteo G, Onofrj M. Thomas A, et al. Among authors: onofrj m. Clin Neuropharmacol. 2001 Jan-Feb;24(1):31-42. doi: 10.1097/00002826-200101000-00007. Clin Neuropharmacol. 2001. PMID: 11290880 Clinical Trial.

4

Switch-over from tolcapone to entacapone in severe Parkinson's disease patients.

Onofrj M, Thomas A, Iacono D, Di Iorio A, Bonanni L. Onofrj M, et al. Eur Neurol. 2001;46(1):11-6. doi: 10.1159/000050749. Eur Neurol. 2001. PMID: 11455177

5

Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium.

Bonanni L, Thomas A, Onofrj M. Bonanni L, et al. Among authors: onofrj m. Neurology. 2006 May 9;66(9):1455; author reply 1455. doi: 10.1212/01.wnl.0000224698.67660.45. Neurology. 2006. PMID: 16682691 No abstract available.

6

Visual hallucinations in Parkinson's disease: clues to separate origins.

Onofrj M, Bonanni L, Albani G, Mauro A, Bulla D, Thomas A. Onofrj M, et al. J Neurol Sci. 2006 Oct 25;248(1-2):143-50. doi: 10.1016/j.jns.2006.05.025. Epub 2006 Jun 23. J Neurol Sci. 2006. PMID: 16806269 Review.

7

End-of-dose deterioration in non ergolinic dopamine agonist monotherapy of Parkinson's disease.

Thomas A, Bonanni L, Di Iorio A, Varanese S, Anzellotti F, D'Andreagiovanni A, Stocchi F, Onofrj M. Thomas A, et al. Among authors: onofrj m. J Neurol. 2006 Dec;253(12):1633-9. doi: 10.1007/s00415-006-0320-z. J Neurol. 2006. PMID: 17219034 Clinical Trial.

8

Symptomatic REM sleep behaviour disorder.

Thomas A, Bonanni L, Onofrj M. Thomas A, et al. Among authors: onofrj m. Neurol Sci. 2007 Jan;28 Suppl 1:S21-36. doi: 10.1007/s10072-007-0735-y. Neurol Sci. 2007. PMID: 17235429

9

Dopa-responsive pseudo-orthostatic tremor in parkinsonism.

Thomas A, Bonanni L, Antonini A, Barone P, Onofrj M. Thomas A, et al. Among authors: onofrj m. Mov Disord. 2007 Aug 15;22(11):1652-6. doi: 10.1002/mds.21621. Mov Disord. 2007. PMID: 17579364

10

Botulinum toxin treatment of lateral axial dystonia in Parkinsonism.

Bonanni L, Thomas A, Varanese S, Scorrano V, Onofrj M. Bonanni L, et al. Among authors: onofrj m. Mov Disord. 2007 Oct 31;22(14):2097-103. doi: 10.1002/mds.21694. Mov Disord. 2007. PMID: 17685467 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

425 results

Search Page

Filters